| (Values in U.S. Thousands) | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 | Mar, 2020 |
| Sales | 1,920 | 960 | 140 | 0 | 0 |
| Sales Growth | +100.00% | +585.71% | unch | unch | unch |
| Net Income | -30,550 | -19,810 | -18,460 | -21,130 | -15,390 |
| Net Income Growth | -54.22% | -7.31% | +12.64% | -37.30% | -27.72% |
Chiasma Inc (CHMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Chiasma, Inc. is a biopharmaceutical company. The company's TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.
Fiscal Year End Date: 12/31